ALLK - Allakos Inc.
| Previous close | 4.7500 |
| Open | 4.7700 |
| Bid | 4.9400 x 800 |
| Ask | 4.9500 x 1100 |
| Day's range | 4.7500 - 5.0000 |
| 52-week range | 2.5400 - 8.7300 |
| Volume | |
| Avg. volume | 1,160,036 |
| Market cap | 430.638M |
| Beta (5Y monthly) | 0.43 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.9300 |
| Earnings date | 02 Aug 2023 - 07 Aug 2023 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 9.00 |
Simply Wall St.Allakos Inc. (NASDAQ:ALLK) has caught the attention of institutional investors who hold a sizeable 45% stake
Key Insights Significantly high institutional ownership implies Allakos' stock price is sensitive to their trading...
Motley FoolWhy Allakos Stock Skyrocketed Nearly 9% Higher Today
Allakos (NASDAQ: ALLK) finished the trading week in style, with its stock price climbing by just under 9% on Friday. The prognosticator getting notably more bullish on Allakos was Jefferies' Maury Raycroft, who upped his recommendation on the clinical-stage biotech's stock to buy from his previous hold.
GlobeNewswireAllakos Provides Business Update and Reports First Quarter 2023 Financial Results
SAN CARLOS, Calif., May 09, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the first quarter ended March 31, 2023. Recent Allakos Events Continued enrollment of a Phase 2 randomized, double-blind, placebo-controlled study of subcutaneous lirentelimab in patients with moderate-to-severe atop
Motley FoolWhy Allakos Stock Was Heating Up Today
Although Allakos reported a net loss of $43 million in the fourth quarter of 2022, investors were more concerned with the progress of the company's clinical pipeline. More specifically, Allakos reaffirmed today that it expects to report trial results from a pair of ongoing mid-stage studies for its lead compound, lirentelimab, in the second half of 2023. The monoclonal antibody is presently in a phase 2 trial as a treatment for atopic dermatitis and a phase 2b trial for chronic spontaneous urticaria (hives).
- GlobeNewswire
Allakos Provides Business Update and Reports Fourth Quarter and Full Year 2022 Financial Results
SAN CARLOS, Calif., March 06, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the fourth quarter and full year ended December 31, 2022. The Company’s most advanced antibodies are lirentelimab (AK002) and AK006. Recent Allakos Events Initiated a Phase 2b randomized, double-blind, placebo-cont
- Simply Wall St.
Is Allakos Inc. (NASDAQ:ALLK) Expensive For A Reason? A Look At Its Intrinsic Value
How far off is Allakos Inc. ( NASDAQ:ALLK ) from its intrinsic value? Using the most recent financial data, we'll take...
- Simply Wall St.
Is Allakos (NASDAQ:ALLK) In A Good Position To Deliver On Growth Plans?
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
ZacksAllakos Inc. (ALLK) Moves to Buy: Rationale Behind the Upgrade
Allakos Inc. (ALLK) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
- GlobeNewswire
Allakos Announces Publication of AK006 Mechanism of Action Manuscript in Communications Biology
– AK006 is an agonistic antibody that targets the mast cell inhibitory receptor Siglec-6 –– AK006 shows deep mast cell inhibition in pre-clinical studies and was engineered to have antibody-dependent cellular phagocytosis (ADCP) activity –– Allakos plans to initiate the first-in-human study of AK006 during 1H 2023 – SAN CARLOS, Calif., Nov. 29, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology company developing therapeutics which target immunomodulatory recept
- GlobeNewswire
Allakos Presents Preclinical Data on AK007, a Siglec-10 Antagonist Antibody, at the Society for Immunotherapy of Cancer’s 37th Annual Meeting
– Siglec-10 is a myeloid checkpoint receptor selectively expressed on tumor associated macrophages and dendritic cells –– AK007 potently blocks all known ligand interaction with Siglec-10, including the “don’t eat me” signal CD24 –– Monotherapy treatment with a Siglec-10 antagonist antibody polarized tumor-associated myeloid cells and reduced tumor burden in pre-clinical studies – SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a clinical-stage biotechnology co
- GlobeNewswire
Allakos Provides Business Update and Reports Third Quarter 2022 Financial Results
SAN CARLOS, Calif., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2022. Recent Allakos Events Allakos’s lirentelimab clinical development is focused on atopic dermatitis and chronic spontaneous urticaria. Initiated a Phase 2b randomized,
- Simply Wall St.
After losing 95% in the past year, Allakos Inc. (NASDAQ:ALLK) institutional owners must be relieved by the recent gain
A look at the shareholders of Allakos Inc. ( NASDAQ:ALLK ) can tell us which group is most powerful. And the group that...
- GlobeNewswire
Allakos Announces Pricing of $150 Million Underwritten Offering of Common Stock
SAN CARLOS, Calif., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the pricing of an underwritten offering of 29,882,000 shares of its common stock at an offering price of $5.02 per share. Investors who have agreed to purchase shares in the offering include Logos Capital, Alta Partners, Braidwell LP, BVF Partners L.P., Commodore Capital, Deep
GlobeNewswireAllakos Announces Initiation of Phase 2b Clinical Trial of Subcutaneous Lirentelimab in Chronic Spontaneous Urticaria (CSU)
Top-line Phase 2b results expected in the second half of 2023 Figure 1 - Change from baseline in UAS7 in omalizumab naïve cohort (n=13) Source: Allakos Inc. Figure 2 - UCT and UAS7 response in Omalizumab Naïve Cohort (n=13) Source: Allakos Inc. Figure 3 - Change from baseline in UAS7 in omalizumab refractory cohort (n=7) Source: Allakos Inc. SAN CARLOS, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for th
- GlobeNewswire
Allakos Announces Topline Phase 3 Data from the EoDyssey Study in Patients with Eosinophilic Duodenitis
– Lirentelimab met histologic co-primary endpoint but missed symptomatic co-primary endpoint – SAN CARLOS, Calif., Sept. 09, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today reported data from EoDyssey, a 24-week, Phase 3, randomized, double-blind, placebo-controlled study of lirentelimab in patients with biopsy confirmed eosinophilic duodenitis (E
- Motley Fool
Why Allakos Stock Is on Fire Today
Specifically, the clinical-stage immunomodulatory receptor specialist's stock price was up by a healthy 24.7%, on heavy volume, as of 1:15 p.m. ET Wednesday afternoon. After all, Allakos stock has been a prime short-seller target ever since the biotech's late-stage monoclonal antibody lirentelimab missed the goalpost as a treatment for eosinophilic gastrointestinal diseases late last year. This small-cap biotech is the epitome of a high-risk, high-reward play.
- GlobeNewswire
Allakos Provides Business Update and Reports Second Quarter 2022 Financial Results
SAN CARLOS, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today provided a business update and reported financial results for the second quarter ended June 30, 2022. Recent Allakos Events Submitted End-of-Phase 2 briefing package to FDA to discuss Phase 2 KRYPTOS data and development pathway of lirentelimab in patients with eosinophil
- GlobeNewswire
Allakos Announces the Appointment of Dr. Amy Ladd to its Board of Directors
SAN CARLOS, Calif., July 25, 2022 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing lirentelimab (AK002) and AK006 for the treatment of allergic and inflammatory diseases, today announced the appointment of Amy L. Ladd, M.D., orthopaedic surgeon and professor at Stanford University, to the Allakos board of directors. “We are very pleased to have such an accomplished physician as Dr. Ladd join our board. Her extensive medical background and expert
- Simply Wall St.
Companies Like Allakos (NASDAQ:ALLK) Could Be Quite Risky
Just because a business does not make any money, does not mean that the stock will go down. For example, although...